Submit a Letter to the Editor for:
Eduardo Lopez Granados, Andrea S. Porpiglia, Mary Beth Hogan, Nuria Matamoros, Silvia Krasovec, Claudio Pignata, C.I.E. Smith, Lennart Hammarstrom, Janne Bjorkander, Bernd H. Belohradsky, G. Fontan Casariego, M.C. Garcia Rodriguez, Mary Ellen Conley
J Clin Invest. 2002;
110(7):1029
doi:10.1172/JCI15658
Abstract |
Full text
|
PDF
A
utosomal recessive disorders of B cell development are rare and heterogeneous. To determine the proportion of affected patients who have defects in the μ heavy chain (IGHM) gene, we used single-stranded conformational polymorphism analysis to screen genomic DNA from 40 unrelated patients with early onset infections, profound hypogammaglobulinemia, and absent B cells. All of the patients were genotypically normal in BTK, the gene that underlies X-linked agammaglobulinemia. Eight different mutations in the μ heavy chain were identified in 19 members of 12 unrelated families. Four of the mutations were large deletions that removed more than 40 kb of DNA in the IGHM locus. In six of the 12 families, the affected patients had an identical single base pair substitution, a G→A, at the –1 position of the alternative splice site. Immunoglobulin haplotype analysis showed that this mutation occurred on at least three different haplotypes, indicating that this is a hot spot for mutations. Compared with patients with mutations in Btk, patients with defects in the μ heavy chain had an earlier onset of disease and more complications. Our study indicates that at least 20–30% of patients with autosomal recessive defects in B cell development have mutations in the μ heavy chain.
Guidelines:
The Editorial Board will only consider letters that we deem relevant and of interest to our readers. We will not post data that have not been subjected to peer review, nor will we post letters that are essentially a reiteration of another letter. All accepted letters will be posted on our website within one week of acceptance. The Editors reserve the right to edit any letter for length, content, and clarity. Authors of all accepted letters will be asked to preview any changes. Authors will be notified by e-mail if their letters were not accepted. As this is a final decision, no appeals will be considered.
Specific requirements: All letters must be 400 words or fewer. You may enter the letter as plain text or HTML, if you wish. The author's name and e-mail address are required, and will be posted with the letter. All possible conflicts of interest must be noted, even if they are not posted. If you wish to include a figure (keep in mind that non-peer-reviewed data will not be posted), please contact the editor directly at editors@the-jci.org.
